Market Place
Sourcing Support
Venatorx and Melinta Provide Update on Status of NDA for Cefepime-Taniborbactam
23 Feb 2024 //
BUSINESSWIRE
New England Journal of Medicine Publishes Positive Results of Cefepime-Taniborbactam from Phase 3
20 Feb 2024 //
BUSINESSWIRE
Venatorx and Menarini Enter Agreement for Cefepime-Taniborbactam
09 Jan 2024 //
BUSINESSWIRE
Everest Announces NMPA Recommends Priority Review for Cefepime-Taniborbactam
19 Sep 2023 //
PR NEWSWIRE
Venatorx Receives FDA Acceptance of NDA for Cefepime-Taniborbactam
15 Aug 2023 //
PR NEWSWIRE
Venatorx Announces FDA Acceptance of NDA for Cefepime-Taniborbactam
15 Aug 2023 //
BUSINESSWIRE
Venatorx Presents Data on Investigational Cefepime-Taniborbactam at IDWeek 2022
20 Oct 2022 //
BUSINESSWIRE
Venatorx Reports Positive Results from Phase 3 Cefepime-Taniborbactam Trial
10 Mar 2022 //
PRNEWSWIRE
Venatorx Pharma to Present Data on Cefepime-Taniborbactam at IDWeek 2020
21 Oct 2020 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.